Compare Deutsche Bank AG (DB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs TransMedics Group Inc — how do they compare? Deutsche Bank AG trades at $35.81 (market cap $68.51B), while TransMedics Group Inc trades at $74.59 (market cap $2.58B). The key difference: Deutsche Bank AG is far larger — about 26.6× TransMedics Group Inc's market cap, and Deutsche Bank AG pays a 3.26% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DB | TMDX | |
|---|---|---|
Market Cap | $68.51B | $2.58B |
Sector | Financials | Technology |
52-Week High | $40.33 | $150.42 |
52-Week Low | $28.37 | $61.99 |
Dividend Yield | 3.26% | — |
Enterprise Value | — | $2.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $35.24, down 1.48% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows attractive valuation metrics with a P/E of 9.79 and P/B of 0.76. Recent quarterly earnings have consistently beaten expectations, and the company announced a $1.00 dividend for H1-26. However, 2024 cash flow was negative $33.10 billion, though it improved to a positive $7.6 billion in 2025.
The outlook is mixed; strong profitability and earnings beats support upside, but regulatory scrutiny and volatile cash flows pose risks. Analyst consensus is cautious with 57.58% hold ratings. The stock's low valuation may appeal to value investors, yet headline risks from recent legal searches require monitoring.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
